FY2024 EPS Estimates for Personalis Reduced by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of Personalis in a research note issued on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.37) for the year, down from their prior forecast of ($1.01). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.46) EPS and FY2027 earnings at ($0.04) EPS.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same period last year, the firm posted ($0.51) EPS.

A number of other equities research analysts have also recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $7.25 price objective on shares of Personalis in a research note on Thursday, November 7th. BTIG Research upped their price target on shares of Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research note on Friday, August 16th.

Personalis Price Performance

Shares of Personalis stock opened at $4.92 on Monday. Personalis has a 1-year low of $1.00 and a 1-year high of $7.20. The business’s fifty day moving average price is $5.12 and its two-hundred day moving average price is $3.39. The company has a market capitalization of $261.15 million, a P/E ratio of -2.93 and a beta of 1.94.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC lifted its holdings in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after acquiring an additional 723,637 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock valued at $1,237,000 after buying an additional 66,128 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Personalis by 144.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock valued at $1,224,000 after acquiring an additional 485,822 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of Personalis by 6.2% during the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after purchasing an additional 24,498 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Personalis by 98.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 108,788 shares of the company’s stock valued at $585,000 after purchasing an additional 53,965 shares during the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.